ZURICH, Switzerland, July 31, 2026 (GLOBE NEWSWIRE) -- NewcelX Ltd. (Nasdaq: NCEL), a clinical-stage biopharmaceutical company developing stem cell-based therapies for type 1 diabetes, today announced that it has entered into securities purchase agreements for a private placement at a purchase price of $4.033 per share, representing a 20% premium to the last closing price of the Company’s common shares on July 30, 2026..

瑞士苏黎世，2026年7月31日（环球电讯社）——NewcelX有限公司（纳斯达克股票代码：NCEL），一家致力于开发基于干细胞的1型糖尿病疗法的临床阶段生物制药公司，今日宣布已签订证券购买协议，进行私募配售，每股购买价格为4.033美元，较该公司普通股在2026年7月30日的最后收盘价溢价20%。

Pursuant to the terms of the securities purchase agreements, the Company is selling an aggregate of 347,134 common shares and one series of warrants to purchase an aggregate of 347,134 common shares at an exercise price of $4.437 per share, which is 132% of the last closing price of the Company’s common shares on July 30, 2026..

根据证券购买协议的条款，公司正在出售总计347,134股普通股，以及一系列认股权证，该等认股权证可用于以每股4.437美元的行权价格购买总计347,134股普通股，该行权价格为公司普通股在2026年7月30日最后收盘价的132%。

The offering includes participation from existing shareholders and is expected to close on or about Aug 14, 2026, subject to the satisfaction of customary closing conditions.

本次发行包括现有股东的参与，预计将于2026年8月14日或左右完成，但须满足惯常的交割条件。

The Company intends to use the net proceeds from the offering, together with its current cash position, and previously announced $25 million equity line, primarily to advance NCEL-101, NewcelX’s lead program for type 1 diabetes, in collaboration with Eledon Pharmaceuticals, and for working capital and general corporate purposes..

公司拟将本次发行的净收益，连同其现有现金状况及此前宣布的2,500万美元股权融资额度，主要用于与Eledon Pharmaceuticals合作推进NewcelX的核心项目NCEL-101（针对1型糖尿病），并用于营运资金及一般企业用途。

“We are very pleased to price this financing at a 20% premium to market with the participation of existing shareholders and new long-term investors,”

“我们非常高兴能够在现有股东和新的长期投资者参与下，以较市场价溢价20%的水平为此次融资定价。”

said Ronen Twito, CEO & Executive Chairman of NewCelX

NewCelX 首席执行官兼执行董事长罗南·特维托表示

. “We believe their support reflects growing confidence in our strategy, our recent achievements, including the successful FDA Pre-IND meeting for NCEL-101, and the long-term potential of our type 1 diabetes program. This financing provides additional resources to advance NCEL-101 toward IND-enabling studies as we continue working to bring a potential cure for type 1 diabetes closer to patients.”.

“我们相信，他们的支持反映了市场对我们战略、近期成就（包括NCEL-101项目成功完成美国食品药品监督管理局的pre-IND会议）以及我们1型糖尿病项目长期潜力的信心日益增强。此次融资为我们提供了额外资源，以推动NCEL-101开展新药临床试验申请（IND）所需的研究，同时我们继续致力于让1型糖尿病的潜在治愈方案更早惠及患者。”

The securities described above are being issued in a private placement under Section 4(a)(2) of the Securities Act of 1933, as amended (the 'Securities Act'), and Regulation D promulgated thereunder and have not been registered under the Securities Act, or applicable state securities laws. Accordingly, the securities may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws..

上述证券正根据经修订的《1933年证券法》（以下简称“《证券法》”）第4(a)(2)条以及据此颁布的D条例以私募方式发行，且未依据《证券法》或适用的州证券法进行注册。因此，除非依据有效的注册声明或符合《证券法》及相应州证券法规定的注册要求豁免，否则不得在美国境内要约或出售该等证券。

This press release does not constitute an offer to sell or a solicitation of an offer to buy the securities in this offering, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction..

本新闻稿不构成出售要约或购买本次发行证券的要约邀请，在任何此类要约、邀请或销售根据该州或其他司法管辖区的证券法进行注册或资格认定之前属于违法的任何州或其他司法管辖区内，均不得进行这些证券的销售。

About NewcelX

关于 NewcelX

NewcelX is an innovative biopharmaceutical company focused on developing transformative stem-cell-derived therapies for Type 1 Diabetes. Built on a validated human pluripotent stem cell (hPSC) platform, the Company’s lead program, NCEL-101, is designed to restore functional insulin production through scalable, off-the-shelf cell replacement.

NewcelX 是一家创新的生物制药公司，专注于开发用于1型糖尿病的变革性干细胞衍生疗法。基于已验证的人多能干细胞（hPSC）平台，公司的核心项目 NCEL-101 旨在通过可规模化、现成可用的细胞替代疗法恢复功能性胰岛素生产。

NewcelX is advancing a comprehensive therapeutic approach for Type 1 Diabetes integrating cell therapy, immune protection, and translational science to address critical unmet medical needs..

NewcelX 正在推进一种针对 1 型糖尿病的综合治疗方案，整合细胞疗法、免疫保护和转化科学，以满足迫切的未竟医疗需求。

Social Media:

社交媒体：

LinkedIn

领英

,

，

Facebook

脸书

,

，

X

X

,

，

Instagram

Instagram

Website:

网站：

www.newcelx.com

www.newcelx.com

Forward-Looking Statements

前瞻性陈述

This press release contains expressed or implied forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other applicable securities laws. For example, NewcelX is using forward-looking statements when it discusses the timing and completion of the offering, the satisfaction of customary closing conditions related to the offering and the intended use of proceeds therefrom.

本新闻稿包含根据1995年《私人证券诉讼改革法》及其他适用证券法律定义的明示或暗示的前瞻性陈述。例如，NewcelX在讨论此次发行的时间安排和完成情况、与此次发行相关的惯例交割条件的满足情况以及募集资金的预期用途时，均使用了前瞻性陈述。

These forward-looking statements and their implications are based on the current expectations of the management of NewcelX and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: the regulatory pathways that NewcelX may elect to utilize in seeking European Medicines Agency, the FDA, and other regulatory approvals; its ability to drive revenue growth, enhance research and development capabilities, and improve financial performance is subject to uncertainties; that its financial position raises substantial doubt about its ability to continue as a going concern; its ability to maintain listing and effectively comply with the listing requirements of the Nasdaq; changes in technology and market requirements; potential delays or obstacles in launching or completing clinical trials, including its expectations regarding the timing of commencing further clinical trials, the process entailed in conducting each such trial, including dosages, and the order of such trials with each of its product candidates or whether such trials will be conducted at all; competitive companies, technologies and its industry; the developm.

这些前瞻性陈述及其影响基于NewcelX管理层的当前预期，并受多种因素和不确定性的影响，可能导致实际结果与前瞻性陈述中描述的结果存在重大差异。除其他因素外，以下因素可能导致实际结果与前瞻性陈述中描述的结果存在重大差异：NewcelX在寻求欧洲药品管理局、美国食品药品监督管理局（FDA）及其他监管机构批准时可能选择的监管路径；其推动收入增长、增强研发能力以及改善财务表现的能力存在不确定性；其财务状况令人对其持续经营能力产生重大疑虑；其维持纳斯达克上市地位并有效遵守上市要求的能力；技术和市场需求的变化；在启动或完成临床试验方面可能出现的延误或障碍，包括其对启动进一步临床试验时间的预期、开展每项此类试验所涉及的过程（包括剂量）、针对各候选产品进行此类试验的顺序，以及是否最终会开展此类试验；竞争对手、技术及其所在行业；开发。

Investor Contact

投资者联系

KCSA Strategic Communications

KCSA战略传播

Valter Pinto, Managing Director

瓦尔特·平托，董事总经理

PH: (212) 896-1254

电话：(212) 896-1254

NewCelX@kcsa.com

NewCelX@kcsa.com

Company Contact

公司联系人

Sarah Bazak

萨拉·巴扎克

InvestorRelations@newcelx.com

投资者关系@newcelx.com